Cenicriviroc for COVID-19: real-time analysis of 3 studies

Download Image

Post

c19early.org

Cenicriviroc for COVID-19

3 studies with >1,000 patients

Serious outcome risk

Cenicriviroc

Control

COVID-19 Cenicriviroc studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (3)−28%

Mortality (3)−28%

Hospitalization (1)−17%

Recovery (3)−2%

RCTs (3)−28%

RCT mortality (3)−28%

Late (3)−28%

00.511.5+

← Cenicriviroc
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


	Covid Analysis	Meta-analysis of cenicriviroc studies
	Meta-analysis of cenicriviroc studies
Jul 25 2023	O’Halloran et al., JAMA, doi:10.1001/jama.2023.11043	Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia
	30% higher mortality (p=0.15), 8% worse improvement (p=0.62), and 1% improved recovery (p=0.91). RCT 723 hospitalized COVID-19 patients showing no significant difference in outcomes with cenicriviroc treatment.
Mar 31 2023	Kurth et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2022.12.004	Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial
	500% higher need for oxygen therapy (p=0.26), 100% worse recovery (p=0.55), and 17% longer hospitalization (p=0.42). RCT 30 hospitalized COVID-19 patients showing no significant difference in clinical improvement with cenicriviroc (CVC) treatment compared to placebo.
Mar 3 2023	Files et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101889	Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
	24% higher mortality (p=0.28) and 14% worse recovery (p=0.46). RCT 261 severe COVID-19 patients showing no significant difference in outcomes with cenicriviroc.